Suppr超能文献

局部晚期鼻窦鳞状细胞癌和鼻窦未分化癌的诱导化疗:一项综述

Induction Chemotherapy for Locoregionally Advanced Sinonasal Squamous Cell Carcinoma and Sinonasal Undifferentiated Carcinoma: A Comprehensive Review.

作者信息

Melder Katie L, Geltzeiler Mathew

机构信息

Department of Otolaryngology-Head and Neck Surgery, Oregon Health & Science University, Portland, OR 97239, USA.

出版信息

Cancers (Basel). 2023 Jul 26;15(15):3798. doi: 10.3390/cancers15153798.

Abstract

Sinonasal squamous cell carcinoma (SNSCC) and sinonasal undifferentiated carcinoma (SNUC) are two of the most common, high-grade malignancies of the sinonasal cavity. The standard of care for resectable lesions per the National Comprehensive Cancer Network (NCCN) guidelines includes surgical resection with negative margins plus adjuvant radiation therapy. However, surgery for locally advanced disease with both orbital and intracranial involvement is associated with significant morbidity and poor overall survival. Over the last decade, induction chemotherapy (IC) has emerged as part of a multimodal treatment strategy to optimize locoregional disease control and minimize substantial surgical morbidity such as orbital exenteration without compromising rates of overall survival. The response to IC both guides additional therapy and helps prognosticate a patient's disease. This narrative review examines the data surrounding the management of patients with SNSCC and SNUC. The pros and cons of upfront surgical management plus adjuvant therapy will be explored, and the case for IC will be presented. The IC-specific regimens and treatment paradigms for SNSCC and SNUC will each be explored in detail. Organ preservation, treatment morbidity, and survival data will be presented, and evidence-based recommendations will be presented for the management of these patients.

摘要

鼻窦鳞状细胞癌(SNSCC)和鼻窦未分化癌(SNUC)是鼻窦腔最常见的两种高级别恶性肿瘤。根据美国国立综合癌症网络(NCCN)指南,可切除病变的标准治疗方案包括手术切除切缘阴性加辅助放疗。然而,对于伴有眼眶和颅内受累的局部晚期疾病进行手术,会带来显著的发病率且总体生存率较差。在过去十年中,诱导化疗(IC)已成为多模式治疗策略的一部分,以优化局部区域疾病控制,并在不影响总体生存率的情况下,将诸如眶内容摘除术等严重手术发病率降至最低。对诱导化疗的反应既指导进一步治疗,也有助于预测患者的疾病情况。本叙述性综述探讨了围绕SNSCC和SNUC患者管理的数据。将探讨 upfront 手术管理加辅助治疗的利弊,并阐述诱导化疗的理由。将分别详细探讨SNSCC和SNUC的诱导化疗特定方案和治疗模式。将呈现器官保留、治疗发病率和生存数据,并为这些患者的管理提出基于证据的建议。

相似文献

2
The Role of Induction Therapy for Sinonasal Cancers.诱导治疗在鼻腔鼻窦癌中的作用。
Curr Treat Options Oncol. 2023 Mar;24(3):162-169. doi: 10.1007/s11864-022-01046-z. Epub 2023 Jan 25.
3
Induction Chemotherapy for Orbit Preservation in Sinonasal Squamous Cell Carcinoma.鼻窦鳞状细胞癌眼眶保留的诱导化疗
J Neurol Surg Rep. 2021 Sep 29;82(3):e36-e37. doi: 10.1055/s-0041-1736160. eCollection 2021 Jul.
5
Sinonasal Undifferentiated Carcinoma.鼻腔鼻窦未分化癌。
Curr Oncol Rep. 2019 Feb 26;21(3):26. doi: 10.1007/s11912-019-0776-4.
10
Oncology for the rhinologist.鼻科学中的肿瘤学。
Curr Opin Otolaryngol Head Neck Surg. 2024 Feb 1;32(1):14-19. doi: 10.1097/MOO.0000000000000951. Epub 2023 Dec 6.

本文引用的文献

7
SMARCA4/BRG1-Deficient Sinonasal Carcinoma.SMARCA4/BRG1缺陷型鼻窦癌
Arch Pathol Lab Med. 2022 Sep 1;146(9):1122-1130. doi: 10.5858/arpa.2021-0001-OA.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验